ArticleBiosecurity and bioterrorism : biodefense strategy, practice, and science2010
Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria.
Article in Biosecurity and bioterrorism : biodefense strategy, practice, and science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- Engineered Bacteriophages: A Next-Generation Platform for Precision Antimicrobials and Therapeutics.Viruses · 2026Review
- Generating STEC-SpecificViruses · 2025Article
- Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.Infectious disease reports · 2024Review
- A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.Antibiotics (Basel, Switzerland) · 2024Review
- Data-Driven Engineering of Phages with Tunable Capsule Tropism for Klebsiella pneumoniae.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Genetic Engineering and Biosynthesis Technology: Keys to Unlocking the Chains of Phage Therapy.Viruses · 2023Review
- Article
- RNA epitranscriptomics dysregulation: A major determinant for significantly increased risk of ASD pathogenesis.Frontiers in neuroscience · 2023Article
- Control of λ LysogenicACS synthetic biology · 2022Article
- Evaluation of a direct phage DNA detection-based Taqman qPCR methodology for quantification of phage and its application in rapid ultrasensitive identification of Acinetobacter baumannii.BMC infectious diseases · 2022Article
- Autism spectrum disorders pathogenesis: Toward a comprehensive model based on neuroanatomic and neurodevelopment considerations.Frontiers in neuroscience · 2022Article
- Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- Luminescent Phage-Based Detection ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Enhancing phage therapy through synthetic biology and genome engineering.Current opinion in biotechnology · 2021Review
- Maternal malnutrition and anaemia in India: dysregulations leading to the 'thin-fat' phenotype in newborns.Journal of nutritional science · 2021Review
- Review
- Galaxy and Apollo as a biologist-friendly interface for high-quality cooperative phage genome annotation.PLoS computational biology · 2020Article
- Engineered bacteriophages as programmable biocontrol agents.Current opinion in biotechnology · 2020Review
- Biological challenges of phage therapy and proposed solutions: a literature review.Expert review of anti-infective therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural outbreaks of multidrug-resistant microorganisms can cause widespread devastation, and several can be used or engineered as agents of bioterrorism. From a biosecurity standpoint, the capacity to detect and then efficiently control, within hours, the spread and the potential pathological effects of an emergent outbreak, for which there may be no effective antibiotics or vaccines, become key challenges that must be met. We turned to phage engineering as a potentially highly flexible and effective means to both detect and eradicate threats originating from emergent (uncharacterized) bacterial strains. To this end, we developed technologies allowing us to (1) concurrently modify multiple regions within the coding sequence of a gene while conserving intact the remainder of the gene, (2) reversibly interrupt the lytic cycle of an obligate virulent phage (T4) within its host, (3) carry out efficient insertion, by homologous recombination, of any number of engineered genes into the deactivated genomes of a T4 wild-type phage population, and (4) reactivate the lytic cycle, leading to the production of engineered infective virulent recombinant progeny. This allows the production of very large, genetically engineered lytic phage banks containing, in an E. coli host, a very wide spectrum of variants for any chosen phage-associated function, including phage host-range. Screening of such a bank should allow the rapid isolation of recombinant T4 particles capable of detecting (ie, diagnosing), infecting, and destroying hosts belonging to gram-negative bacterial species far removed from the original E. coli host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.